Research on Mechanism of FGFR1 Inhibitor BAY1163877 against Proliferation of Breast Cancer Cells

Melanie Heroult, Peter Ellinghaus, Christian Sieg, Dirk Brohm, Sylvia Gruenewald, Marie-Pierre Collin, Ulf Boemer, Mario Lobell, Walter Huebsch, Matthias Ocker, Stuart Ince, Andrea Haegebarth, Rolf Jautelat, Holger Hess-Stumpp, Michael Brands, Karl Ziegelbauer, Abstract 1739: Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial Cancer Research. ,vol. 74, pp. 1739- 1739 ,(2014) , 10.1158/1538-7445.AM2014-1739

SEUNG-YOUN JUNG, JAE YOUN YI, MI-HYOUNG KIM, KYUNG-HEE SONG, SEONG-MOOK KANG, JIYEON AHN, SANG-GU HWANG, KY-YOUB NAM, JIE-YOUNG SONG, IM-412 inhibits the invasion of human breast carcinoma cells by blocking FGFR-mediated signaling Oncology Reports. ,vol. 34, pp. 2731- 2737 ,(2015) , 10.3892/OR.2015.4249

Chee Leong Cheng, Aye Aye Thike, Sie Yong Jane Tan, Pei Jou Chua, Boon Huat Bay, Puay Hoon Tan, Expression of FGFR1 is an independent prognostic factor in triple-negative breast cancer. Breast Cancer Research and Treatment. ,vol. 151, pp. 99- 111 ,(2015) , 10.1007/S10549-015-3371-X

Nicholas Turner, Richard Grose, Fibroblast growth factor signalling: from development to cancer. Nature Reviews Cancer. ,vol. 10, pp. 116- 129 ,(2010) , 10.1038/NRC2780

Victoria Knights, Simon J. Cook, De-regulated FGF receptors as therapeutic targets in cancer. Pharmacology & Therapeutics. ,vol. 125, pp. 105- 117 ,(2010) , 10.1016/J.PHARMTHERA.2009.10.001

Fabrice André, Javier Cortés, Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast Cancer Research and Treatment. ,vol. 150, pp. 1- 8 ,(2015) , 10.1007/S10549-015-3301-Y

Min Hye Jang, Eun Joo Kim, Yoomi Choi, Hee Eun Lee, Yu Jung Kim, Jee Hyun Kim, Eunyoung Kang, Sung-Won Kim, In Ah Kim, So Yeon Park, FGFR1 is amplified during the progression of in situ to invasive breast carcinoma. Breast Cancer Research. ,vol. 14, pp. 1- 12 ,(2012) , 10.1186/BCR3239

D.C. Tomlinson, M.A. Knowles, V. Speirs, Mechanisms of FGFR3 actions in endocrine resistant breast cancer International Journal of Cancer. ,vol. 130, pp. 2857- 2866 ,(2012) , 10.1002/IJC.26304

Sara A. Byron, Michael Gartside, Matthew A. Powell, Candice L. Wellens, Feng Gao, David G. Mutch, Paul J. Goodfellow, Pamela M. Pollock, FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features PLOS ONE. ,vol. 7, pp. 30801- ,(2012) , 10.1371/JOURNAL.PONE.0030801

Stevan R. Hubbard, Jeffrey H. Till, Protein Tyrosine Kinase Structure and Function Annual Review of Biochemistry. ,vol. 69, pp. 373- 398 ,(2000) , 10.1146/ANNUREV.BIOCHEM.69.1.373